Literature DB >> 24945162

Do maternal opioids reduce neonatal regional brain volumes? A pilot study.

Q Yuan1, M Rubic1, J Seah1, C Rae2, I M R Wright3, K Kaltenbach4, J M Feller5, M E Abdel-Latif6, C Chu7, J L Oei8.   

Abstract

OBJECTIVE: A substantial number of children exposed to gestational opioids have neurodevelopmental, behavioral and cognitive problems. Opioids are not neuroteratogens but whether they affect the developing brain in more subtle ways (for example, volume loss) is unclear. We aimed to determine the feasibility of using magnetic resonance imaging (MRI) to assess volumetric changes in healthy opioid-exposed infants. STUDY
DESIGN: Observational pilot cohort study conducted in two maternity hospitals in New South Wales, Australia. Maternal history and neonatal urine and meconium screens were obtained to confirm drug exposure. Volumetric analysis of MRI scans was performed with the ITK-snap program. RESULT: Scans for 16 infants (mean (s.d.) gestational age: 40.9 (1.5) weeks, birth weight: 3022.5 (476.6) g, head circumference (HC): 33.7 (1.5 cm)) were analyzed. Six (37.5%) infants had HC <25th percentile. Fourteen mothers used methadone, four used buprenorphine and 11 used more than one opioid (including heroin, seven). All scans were structurally normal whole brain volumes (357.4 (63.8)) and basal ganglia (14.5 (3.5)) ml were significantly smaller than population means (425.4 (4.8), 17.1 (4.4) ml, respectively) but lateral ventricular volumes (3.5 (1.8) ml) were larger than population values (2.1(1.5)) ml.
CONCLUSION: Our pilot study suggests that brain volumes of opioid-exposed babies may be smaller than population means and that specific regions, for example, basal ganglia, that are involved in neurotransmission, may be particularly affected. Larger studies including correlation with neurodevelopmental outcomes are warranted to substantiate this finding.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24945162     DOI: 10.1038/jp.2014.111

Source DB:  PubMed          Journal:  J Perinatol        ISSN: 0743-8346            Impact factor:   2.521


  30 in total

1.  Neonatal abstinence syndrome: assessment and management.

Authors:  L P Finnegan; J F Connaughton; R E Kron; J P Emich
Journal:  Addict Dis       Date:  1975

2.  Severe cerebellitis following methadone poisoning.

Authors:  Fionnghuala Mills; Suzanna C MacLennan; Catherine J Devile; Dawn E Saunders
Journal:  Pediatr Radiol       Date:  2007-10-20

3.  Structural deficits in the emotion circuit and cerebellum are associated with depression, anxiety and cognitive dysfunction in methadone maintenance patients: a voxel-based morphometric study.

Authors:  Wei-Che Lin; Kun-Hsien Chou; Hsiu-Ling Chen; Chu-Chung Huang; Cheng-Hsien Lu; Shau-Hsuan Li; Ya-Ling Wang; Yu-Fan Cheng; Ching-Po Lin; Chien-Chih Chen
Journal:  Psychiatry Res       Date:  2012-03-03       Impact factor: 3.222

4.  Ventricular configuration and cerebral growth in infants born to drug-dependent mothers.

Authors:  M E Pasto; L J Graziani; S L Tunis; J M Deiling; A B Kurtz; B Goldberg; L P Finnegan
Journal:  Pediatr Radiol       Date:  1985

5.  Prescription opioid analgesics rapidly change the human brain.

Authors:  Jarred W Younger; Larry F Chu; Nicole T D'Arcy; Kiley E Trott; Laura E Jastrzab; Sean C Mackey
Journal:  Pain       Date:  2011-04-30       Impact factor: 6.961

6.  Neonatal abstinence syndrome and associated health care expenditures: United States, 2000-2009.

Authors:  Stephen W Patrick; Robert E Schumacher; Brian D Benneyworth; Elizabeth E Krans; Jennifer M McAllister; Matthew M Davis
Journal:  JAMA       Date:  2012-04-30       Impact factor: 56.272

7.  Alterations in brain structure and functional connectivity in prescription opioid-dependent patients.

Authors:  Jaymin Upadhyay; Nasim Maleki; Jennifer Potter; Igor Elman; David Rudrauf; Jaime Knudsen; Diana Wallin; Gautam Pendse; Leah McDonald; Margaret Griffin; Julie Anderson; Lauren Nutile; Perry Renshaw; Roger Weiss; Lino Becerra; David Borsook
Journal:  Brain       Date:  2010-06-16       Impact factor: 13.501

8.  Increasing prevalence of neonatal withdrawal syndrome: population study of maternal factors and child protection involvement.

Authors:  Melissa O'Donnell; Natasha Nassar; Helen Leonard; Ronnie Hagan; Richard Mathews; Yvonne Patterson; Fiona Stanley
Journal:  Pediatrics       Date:  2009-04       Impact factor: 7.124

9.  A structural MRI study of human brain development from birth to 2 years.

Authors:  Rebecca C Knickmeyer; Sylvain Gouttard; Chaeryon Kang; Dianne Evans; Kathy Wilber; J Keith Smith; Robert M Hamer; Weili Lin; Guido Gerig; John H Gilmore
Journal:  J Neurosci       Date:  2008-11-19       Impact factor: 6.167

10.  The developmental outcome of children born to heroin-dependent mothers, raised at home or adopted.

Authors:  A Ornoy; V Michailevskaya; I Lukashov; R Bar-Hamburger; S Harel
Journal:  Child Abuse Negl       Date:  1996-05
View more
  22 in total

Review 1.  Neonatal Adaptation Issues After Maternal Exposure to Prescription Drugs: Withdrawal Syndromes and Residual Pharmacological Effects.

Authors:  Irma Convertino; Alice Capogrosso Sansone; Alessandra Marino; Maria T Galiulo; Stefania Mantarro; Luca Antonioli; Matteo Fornai; Corrado Blandizzi; Marco Tuccori
Journal:  Drug Saf       Date:  2016-10       Impact factor: 5.606

2.  White Matter Injury and Structural Anomalies in Infants with Prenatal Opioid Exposure.

Authors:  S L Merhar; N A Parikh; A Braimah; B B Poindexter; J Tkach; B Kline-Fath
Journal:  AJNR Am J Neuroradiol       Date:  2019-10-17       Impact factor: 3.825

3.  What are the true volumes of SEGA tumors? Reliability of planimetric and popular semi-automated image segmentation methods.

Authors:  Konrad Stawiski; Joanna Trelińska; Dobromiła Baranska; Iwona Dachowska; Katarzyna Kotulska; Sergiusz Jóźwiak; Wojciech Fendler; Wojciech Młynarski
Journal:  MAGMA       Date:  2017-03-20       Impact factor: 2.310

4.  Outcomes of Babies with Opioid Exposure (OBOE): protocol of a prospective longitudinal cohort study.

Authors:  Carla M Bann; Jamie E Newman; Brenda Poindexter; Katherine Okoniewski; Sara DeMauro; Scott A Lorch; Deanne Wilson-Costello; Namasivayam Ambalavanan; Myriam Peralta-Carcelen; Catherine Limperopoulos; Kushal Kapse; Jonathan M Davis; Michele Walsh; Stephanie Merhar
Journal:  Pediatr Res       Date:  2022-08-30       Impact factor: 3.953

5.  Fetal Growth Outcomes in a Cohort of Polydrug- and Opioid-Dependent Patients.

Authors:  Laura Garrison; Lawrence Leeman; Renate D Savich; Hilda Gutierrez; William F Rayburn; Ludmila N Bakhireva
Journal:  J Reprod Med       Date:  2016 Jul-Aug       Impact factor: 0.142

6.  Educational Disabilities Among Children Born With Neonatal Abstinence Syndrome.

Authors:  Mary-Margaret A Fill; Angela M Miller; Rachel H Wilkinson; Michael D Warren; John R Dunn; William Schaffner; Timothy F Jones
Journal:  Pediatrics       Date:  2018-09       Impact factor: 7.124

7.  Opioids affect the fetal brain: reframing the detoxification debate.

Authors:  Steve N Caritis; Ashok Panigrahy
Journal:  Am J Obstet Gynecol       Date:  2019-07-16       Impact factor: 8.661

8.  Pilot study of fetal brain development and morphometry in prenatal opioid exposure and smoking on fetal MRI.

Authors:  Rupa Radhakrishnan; Brandon P Brown; David M Haas; Yong Zang; Christina Sparks; Senthilkumar Sadhasivam
Journal:  J Neuroradiol       Date:  2021-01-05       Impact factor: 3.447

Review 9.  Neuroimaging in infants with prenatal opioid exposure: Current evidence, recent developments and targets for future research.

Authors:  Rupa Radhakrishnan; Gregory Grecco; Kellen Stolze; Brady Atwood; Samuel G Jennings; Izlin Z Lien; Andrew J Saykin; Senthilkumar Sadhasivam
Journal:  J Neuroradiol       Date:  2020-10-13       Impact factor: 3.447

Review 10.  Neonatal Opioid Withdrawal Syndrome (NOWS): A Transgenerational Echo of the Opioid Crisis.

Authors:  Andrew E Weller; Richard C Crist; Benjamin C Reiner; Glenn A Doyle; Wade H Berrettini
Journal:  Cold Spring Harb Perspect Med       Date:  2021-03-01       Impact factor: 6.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.